SCHEMBL19499488

SCHEMBL19499488

Cc1cccc(C(F)(F)F)c1Cc1c[nH]c2ncccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 2/20 0.57
MET P08581 1/20 0.54
FGFR1 P11362 1/20 0.51
FGFR4 P22455 1/20 0.51
CSF1R P07333 1/20 0.49
KIT P10721 1/20 0.49
CDC7 O00311 1/20 0.44
MAP4K4 O95819 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
CDK2 P24941 1/20 0.44
GSK3B P49841 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
HTR2A P28223 3/20 0.43
HTR7 P34969 3/20 0.43
HTR6 P50406 1/20 0.43
MTNR1A P48039 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415187 0.87 GPR84 (0.71) GPR84METFGFR1FGFR4CSF1R
SCHEMBL19471690 0.85 GPR84 (0.57) GPR84METFGFR1FGFR4CSF1R
SCHEMBL19499499 0.80 MEN1 (0.53) GPR84HTR2AHTR6RORCCYP3A4
SCHEMBL415616 0.76 GPR84 (0.71) GPR84METFGFR1FGFR4CSF1R
SCHEMBL1266824 0.75 CSF1R (0.69) GPR84METFGFR1FGFR4CSF1R
SCHEMBL27911675 0.75 GPR84 (1.00) GPR84METFGFR1FGFR4CSF1R
SCHEMBL1266739 0.74 CDC7 (0.60) GPR84METFGFR1FGFR4CSF1R
SCHEMBL1267455 0.74 CSF1R (0.55) GPR84METFGFR1FGFR4CSF1R
SCHEMBL857367 0.73 MET (0.75) GPR84METFGFR1FGFR4CSF1R
SCHEMBL415599 0.73 GPR84 (0.71) GPR84METFGFR1FGFR4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305915-A1 INDAZOLE AND INDOLE DERIVATIVES AS INHIBITORS OF RETINOIC ACID RELATES ORPHAN RECEPTOR GAMMA (ROR GAMMA) FOR THE TREATMENT OF IMMUNE-RELATED DISEASES ORCA PHARMACEUTICALS, LLC 2017-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305915-A1 INDAZOLE AND INDOLE DERIVATIVES AS INHIBITORS OF RETINOIC ACID RELATES ORPHAN RECEPTOR GAMMA (ROR GAMMA) FOR THE TREATMENT OF IMMUNE-RELATED DISEASES RORA, RORB, RORC GPR84 102/4885MET 2322/4885FGFR1 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.